SecProbe.io

CORRESP
1
filename1.htm

Ritter
Pharmaceuticals, Inc.

1880
Century Park East, Suite 1000

Los
Angeles, CA 90067

(310)
203-1000

August
19, 2016

VIA
EDGAR

United
States Securities and Exchange Commission

100
F Street, NE

Washington,
D.C. 20549

Attention:
Suzanne Hayes, Assistant Director

    Re:

    Ritter
    Pharmaceuticals, Inc. – Request for Acceleration

    Registration
    Statement on Form S-3

    File
    No. 333- 213087

Ladies
and Gentlemen:

Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, Ritter Pharmaceuticals, Inc. (the “Registrant”)
hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333- 213087) (the “Registration
Statement”), so that it may become effective at 4:30 p.m. Eastern Standard Time on August 23, 2016, or as soon thereafter
as practicable.

The
Registrant hereby authorizes each of Michael Sanders, Esq., David T. Mittelman, Esq. and Wendy Grasso, Esq. of Reed Smith LLP,
attorneys for the Registrant, to orally modify or withdraw this request for acceleration.

The
Registrant hereby acknowledges that:

    i.
    should
    the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority,
    declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to
    the Registration Statement;

    ii.
    the
    action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective,
    does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration
    Statement; and

    iii.
    the
    Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by
    the Commission or any person under the federal securities laws of the United States.

The
Registrant requests that it be notified of such effectiveness by a telephone call to Wendy Grasso at (212) 549-0216 or, in her
absence, Mr. Sanders at (310) 734-5232 or Mr. Mittelman at (415) 659-5943.

    RITTER
    PHARMACEUTICALS, INC.

    By:
    /s/ Michael
    D. Step

    Michael
    D. Step

    Chief
    Executive Officer

Cc:
Dorrie Yale, SEC Staff